Form 4: Akero Therapeutics CFO Sells Shares to Cover Tax Obligations

Akero Therapeutics' Chief Financial Officer, William Richard White, sold 2,817 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• William Richard White, the Chief Financial Officer of Akero Therapeutics, sold 2,817 shares of common stock on December 10, 2024.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted-average price of $30.79, with individual transactions ranging from $30.79 to $30.99.
• Following the transaction, Mr. White directly owns 38,335 shares of Akero Therapeutics common stock.

Sentiment

Score: 5

Explanation: This is a routine transaction related to tax obligations and does not indicate a change in the company's fundamentals or the executive's confidence in the company.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Sell-to-cover transactions are a common practice among publicly traded companies to manage tax obligations for employees with stock-based compensation.
• The price range of $30.79 to $30.99 is within the typical range for such transactions, reflecting the current market value of Akero Therapeutics stock.
• Similar transactions are regularly reported by executives at comparable biotech companies, such as Madrigal Pharmaceuticals and Viking Therapeutics, when their restricted stock units vest.

Stakeholder Impact

• The sale of shares by the CFO has a minimal impact on shareholders as it is a routine transaction for tax purposes.
• The transaction does not affect the company's operations or financial health.

Key Dates

Keywords

Akero Therapeutics, insider trading, Form 4, stock sale, CFO, William Richard White, tax obligations, restricted stock units